QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
LON:SAR

Sareum Share Forecast, Price & News

GBX 6.25
-0.05 (-0.79 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
5.92
6.30
50-Day Range
6
9.15
52-Week Range
1.08
10
Volume
13.62 million shs
Average Volume
19.79 million shs
Market Capitalization
£210.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive SAR News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.


About Sareum

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
5
Year Founded
N/A

Sales & Book Value

Annual Sales
£47,204.00
Cash Flow
GBX 0.26 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
3,365,701,000
Free Float
N/A
Market Cap
£210.36 million
Next Earnings Date
11/2/2021 (Estimated)
Fiscal Year End
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Sareum (LON:SAR) Frequently Asked Questions

What stocks does MarketBeat like better than Sareum?

Wall Street analysts have given Sareum a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sareum wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sareum's next earnings date?

Sareum is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Sareum
.

How has Sareum's stock been impacted by COVID-19 (Coronavirus)?

Sareum's stock was trading at GBX 0.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SAR shares have increased by 1,949.2% and is now trading at GBX 6.25.
View which stocks have been most impacted by COVID-19
.

Who are Sareum's key executives?

Sareum's management team includes the following people:
  • Dr. Tim J. Mitchell, Founder, CEO & Exec. Director (Age 61, Pay $184.85k)
  • Dr. John C. Reader Ph.D., Founder, Chief Scientific Officer & Exec. Director (Age 54, Pay $183.44k)
  • Mr. Anthony Bunn F.C.M.A., FCMA, Sec.

What other stocks do shareholders of Sareum own?

What is Sareum's stock symbol?

Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR."

How do I buy shares of Sareum?

Shares of SAR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Sareum's stock price today?

One share of SAR stock can currently be purchased for approximately GBX 6.25.

How much money does Sareum make?

Sareum has a market capitalization of £210.36 million and generates £47,204.00 in revenue each year.

How many employees does Sareum have?

Sareum employs 5 workers across the globe.

What is Sareum's official website?

The official website for Sareum is www.sareum.co.uk.

Where are Sareum's headquarters?

How can I contact Sareum?

Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The company can be reached via phone at +44-1223-497700.


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.